Research Article: Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
Introduction:
Anti-vascular endothelial growth factor (anti-VEGF) therapies have helped decrease the risk of legal blindness from neovascular age-related macular degeneration (nARMD) by approximately %. The Food and Drug Administration (FDA) approved faricimab (Vabysmo, RG, Roche/ Genentech, Basel, Switzerland) for the treatment of nARMD and DME on January , . Faricimab inhibits both VEGF-A and angiopoietin (ang)- receptors; Ang- is produced in response to hypoxic stress, interrupting the endothelial cell barrier and…
Read more